# Martin J. Edelman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/martin-j-edelman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,815 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 59 |
| i10-index | 200 |
| Last Known Institution | Fox Chase Cancer Center |
| OpenAlex ID | https://openalex.org/A5063441489 |
| ORCID iD | 0000-0002-3752-0726 |
| Works | 504 |

## Researcher papers

- [A Comparison of Colonoscopy and Double-Contrast Barium Enema for Surveillance after Polypectomy](https://scholariq.org/papers/a-comparison-of-colonoscopy-and-double-contrast-barium-enema-for-surveillance/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)
- [Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/small-cell-lung-cancer-version-2-2022-nccn-clinical-practice-guidelines-in/)
- [A War on Two Fronts: Cancer Care in the Time of COVID-19](https://scholariq.org/papers/a-war-on-two-fronts-cancer-care-in-the-time-of-covid-19/)
- [Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer](https://scholariq.org/papers/stereotactic-body-radiation-therapy-for-operable-early-stage-lung-cancer/)
- [Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study](https://scholariq.org/papers/gefitinib-versus-placebo-in-completely-resected-non-small-cell-lung-cancer/)
- [Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung](https://scholariq.org/papers/results-from-the-phase-iii-randomized-trial-of-onartuzumab-plus-erlotinib-versus/)
- [Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer](https://scholariq.org/papers/second-esmo-consensus-conference-on-lung-cancer-pathology-and-molecular/)
- [Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/chemotherapy-and-survival-benefit-in-elderly-patients-with-advanced-non-small/)
- [Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial](https://scholariq.org/papers/randomized-phase-ii-trial-of-erlotinib-alone-or-with-carboplatin-and-paclitaxel/)
- [Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)](https://scholariq.org/papers/results-of-a-randomized-placebo-controlled-phase-2-study-of-tarextumab-trxt-anti/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Fox Chase Cancer Center](https://scholariq.org/institutions/fox-chase-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.